Saint Louis, Missouri (PRWEB) December 22, 2011
Lee BioSolutions, an international manufacturer, producer and supplier of high purity proteins and antigens announces increased manufacturing capacity for D-Dimer protein. The St. Louis-based biotechnology firm recently developed a proprietary process to effectively and efficiently purify the protein marker for Deep Vein Thrombosis and Pulmonary Embolism detection. As a result, LeeBio is supplying bulk quantities of this critical component for thrombosis tests to major manufacturers for early detection of blood clots to prevent DVT.
According to the Centers of Disease and Control, CDC, Deep Vein Thrombosis and Pulmonary Embolism affects up to 600,000 individuals in the US alone each and every year . What happens in the most serious of cases is Deep Vein Thrombosis is that part of a blood clot breaks off in the leg and travels through the bloodstream to the lungs causing a blockage called pulmonary embolism or PE. DVT/PLE shows no preference to age, gender or ethnicity and is one of those disorders that is repeatedly underdiagnosed causing serious illness, disability and even death. In fact 10% of individuals diagnosed with DVT will die within the first month of diagnosis because they were not treated early enough. With risk factors such as aging population , more sedentary habits among individuals, obesity , this disorder is an important and growing public health concern.
Lee’s new D-Dimer production capabilities enables international diagnostics companies to quickly manufacture serum D-Dimer tests, which are affordable and easy to administer. Lee has scaled up production to meet global market demand.
“Lee Biosolutions is on the forefront of Coagulation disorders and Deep Vein Thrombosis research by supplying a highly purified clot dissolving substance call D-Dimer from human serum “ said Burton Lee, President of Lee Biosolutions . “ The D-Dimer test is used for detecting increased D dimer in your blood is most useful for ruling out deep vein thrombosis or for identifying people at risk of recurrence. “
Lee Biosolutions is also involved with early detection of Diabetes with our new HbA1c antigen and detection of Chronic Kidney Disease with human cystatin C protein and kidney damage marker Beta 2 Microglobulin protein. We are all about saving lives with early detection of clinical diseases.
About Lee BioSolutions, Inc.
Lee BioSolutions is an international producer and supplier of high purity human, animal and recombinant proteins, biological fluids , antibodies and immunoreagents. Headquartered in St. Louis and founded in 1981, the biotechnology firm serves academic and scientific researchers as well as IVD manufacturers worldwide. Lee BioSolutions produces and processes the raw biomaterials used in drug discovery and development, laboratory equipment calibration, clinical diagnosis and product testing. These include human neutrophil elastase, human myeloperoxidase isoform c, alpha fetoprotein, beta 2 Microglobulin